Roche

Roche Terminates Second Phase II Schizophrenia Trial
Roche Terminates Second Phase II Schizophrenia Trial
BioSpace
Roche
schizophrenia
ralmitaront
clinical trials
Flag link:
Gilead picks former Roche executive to run cell therapy unit Kite
Gilead picks former Roche executive to run cell therapy unit Kite
BioPharma Dive
Gilead Sciences
Roche
Kite Pharma
cell therapy
Cindy Perettie
women executives
Flag link:
Roche’s BTK inhibitor succeeds in a Phase II MS trial
Roche’s BTK inhibitor succeeds in a Phase II MS trial
Clinical Trials Arena
Roche
fenebrutinib
clinical trials
MS
relapsing multiple sclerosis
Flag link:
Big Pharma layoffs: BMS, Roche and Takeda axe hundreds of jobs
Big Pharma layoffs: BMS, Roche and Takeda axe hundreds of jobs
Medical Marketing and Media
layoffs
Bristol Myers Squibb
Roche
Takeda
Gossamer Bio
Novavax
Flag link:
2023’s biggest launches: the story so far
2023’s biggest launches: the story so far
EP Vantage
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Flag link:
BioNTech, Roche's experimental pancreatic cancer treatment wins Nature plaudit
BioNTech, Roche's experimental pancreatic cancer treatment wins Nature plaudit
Yahoo/Reuters
BioNTech
Roche
Genentech
pancreatic cancer
MRNA
Nature
vaccines
Flag link:
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
BioSpace
Gilead Sciences
GSK
momelotinib
Roche
Eli Lilly
lebrikizumab
Merck
Zejula
Amgen
Galenica
Veltassa
Cubicin
Flag link:
A blockbuster year could be building
A blockbuster year could be building
EP Vantage
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Flag link:
FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
BioSpace
Roche
Genentech
FDA
Vabysmo
macular edema
retinal vein occlusion
Flag link:
Roche, with HER2 franchise under pressure, pays $70M for breast cancer brain metastases prospect
Roche, with HER2 franchise under pressure, pays $70M for breast cancer brain metastases prospect
Fierce Biotech
Roche
Zion Pharma
brain metastases
breast cancer
Flag link:
Iteos – and GSK – keep the faith
Iteos – and GSK – keep the faith
EP Vantage
GSK
iTeos Therapeutics
anti-TIGIT
Roche
belrestotug
Flag link:
Roche opens new institute to advance research in human model systems
Roche opens new institute to advance research in human model systems
Pharmaceutical Technology
Roche
R&D
organoids
Switzerland
Flag link:
'More in the hopper': European Big Pharmas hint M&A could ramp up
'More in the hopper': European Big Pharmas hint M&A could ramp up
Fierce Biotech
Europe
M&A
GSK
Novartis
Roche
Flag link:
Go or no go? Sarepta’s gene therapy faces scrutiny
Go or no go? Sarepta’s gene therapy faces scrutiny
EP Vantage
Sarepta Therapeutics
gene therapy
SRP-9001
Roche
DMD
Duchenne Muscular Dystrophy
Flag link:
Roche’s new eye drug pressures Eylea with strong launch
Roche’s new eye drug pressures Eylea with strong launch
BioPharma Dive
Roche
Vabysmo
Eylea
earnings
Regeneron
Flag link:
Roche nixes Tecentriq trial in early breast cancer, but it's 'still in the game' in key lung cancer use: exec
Roche nixes Tecentriq trial in early breast cancer, but it's 'still in the game' in key lung cancer use: exec
Fierce Pharma
Roche
Tecentriq
breast cancer
Teresa Graham
Pharma CEOs
Flag link:
Roche, seeing MAGE magic wane, makes pair of solid tumor bispecifics disappear
Roche, seeing MAGE magic wane, makes pair of solid tumor bispecifics disappear
Fierce Biotech
Roche
earnings
solid tumors
MAGE-A4
Flag link:
Drugmakers take sides in Amgen, Regeneron fight over antibody patents
Drugmakers take sides in Amgen, Regeneron fight over antibody patents
BioPharma Dive
Amgen
Regeneron Pharmaceuticals
Sanofi
Supreme Court
patents
Pfizer
Bayer
Roche
Genentech
AstraZeneca
JNJ
Flag link:
Big pharma holds steady on research spending
Big pharma holds steady on research spending
EP Vantage
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Flag link:
Big pharma’s biggest spenders revealed: 2022 edition
Big pharma’s biggest spenders revealed: 2022 edition
EP Vantage
M&A
R&D
AbbVie
AstraZeneca
Bristol Myers Squibb
Eli Lilly
GSK
JNJ
Merck
Novartis
Pfizer
Roche
Sanofi
Flag link:

Pages